NeuroSense Therapeutics (NASDAQ:NRSN) Earns Buy Rating from D. Boral Capital

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $14.00 price target on the stock.

NRSN has been the topic of a number of other research reports. Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 29th. Finally, Roth Mkm assumed coverage on NeuroSense Therapeutics in a research report on Tuesday, March 10th. They set a “buy” rating and a $3.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, NeuroSense Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $8.50.

NeuroSense Therapeutics Stock Down 0.3%

NASDAQ NRSN opened at $0.76 on Wednesday. The stock’s 50-day simple moving average is $0.86 and its two-hundred day simple moving average is $0.98. NeuroSense Therapeutics has a twelve month low of $0.63 and a twelve month high of $2.60. The company has a market capitalization of $24.75 million, a price-to-earnings ratio of -1.41 and a beta of 1.70.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NRSN. Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics in the fourth quarter worth about $77,000. Squarepoint Ops LLC increased its holdings in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares during the period. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics in the second quarter worth about $54,000. Finally, Two Sigma Investments LP purchased a new position in shares of NeuroSense Therapeutics in the third quarter worth about $26,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.